Výsledky vyhledávání - "Donna M. Marinucci"

Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial

Autor: Donna M. Marinucci, Mary Lou Smith, Keith T. Flaherty, Ju-Whei Lee, Peter J. O'Dwyer, Alice P. Chen, Barbara A. Conley, Elda Railey, Carol B. White, Bruce J. Giantonio

Publikováno v: JCO Precis Oncol

PURPOSE To identify factors that may influence physician participation in tumor profiling studies and to assess the routine use of tumor profiling in clinical practice. METHODS Physicians in the National Cancer Institute–Molecular Analysis for Ther

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1947b8129df1860a2e07fb13ecc950e5
https://europepmc.org/articles/PMC7608510/

Zobrazit plný text záznamu

Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology

Autor: Mitchell S. von Itzstein, John R. Howell, Mary Lou Smith, Elda Railey, Donna M. Marinucci, Wendy Lawton, David E. Gerber, George W. Sledge, Nisha Unni, Carol B. White

Publikováno v: Cancer

BACKGROUND: While there is increased attention to designing and explaining clinical trials in ways that are clinically meaningful for patients, there is limited information on patient preferences, understanding and perceptions of this content. METHOD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51af3abf524e5f8e546b17ecd069f5c2
https://pubmed.ncbi.nlm.nih.gov/31967687

Zobrazit plný text záznamu

A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer

Autor: Donna M. Marinucci, Robert L. Comis, Maria-Jose Ribeiro, Ruqin Chen, Rafat Ansari, Mark A. Socinski, Matthew J. Monberg, Joseph Treat, Robert B. Catalano, Coleman K. Obasaju, Darla K. Liles

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(7)

Purpose To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. Patients and Methods Chemonaive patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a613a92299c10371857a708a194da3
https://pubmed.ncbi.nlm.nih.gov/20593535

Zobrazit plný text záznamu

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Autor: Joseph Treat, Kendrith M. Rowland, H. H. Gillenwater, Robert L. Comis, Robert B. Catalano, Donna M. Marinucci, Mark A. Socinski, René Gonin, Chandra P. Belani, Rafat Ansari, Coleman K. Obasaju, Martin J. Edelman

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 21(3)

Background Paclitaxel–carboplatin is used as the standard regimen for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was designed to compare gemcitabine + carboplatin or gemcitabine + paclitaxel to the standard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b1400b1c86c05b6b5239b4697b80455
https://pubmed.ncbi.nlm.nih.gov/19833819

Zobrazit plný text záznamu

A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer

Autor: Chandra P. Belani, Joseph Treat, Coleman K. Obasaju, Martin J. Edelman, Robert L. Comis, Donna M. Marinucci, René Gonin, Ruqin Chen, Rafat Ansari, Mark A. Socinski, Robert B. Catalano, Matthew J. Monberg

Publikováno v: Critical reviews in oncology/hematology. 78(2)

Sufficient data are currently unavailable to assist in defining suitable regimens for patients ≥ 70 years with advanced non-small cell lung cancer (NSCLC).Chemonaïve patients with a performance status (PS) of 0 or 1 and stage IIIB or IV NSCLC were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd13892dd553e3bc3080308071cc17c
https://pubmed.ncbi.nlm.nih.gov/20413322

Zobrazit plný text záznamu

Medically Underrepresented Populations In National Cancer Institute (NCI) Sponsored Cancer Clinical Trials: Refining the Calculation of Accrual Targets

Autor: Judith Manola, Donna M. Marinucci, Robert B. Catalano, Michael S. Katz, Mary Lou Smith, Bruce J. Giantonio, Mary Jackson Scroggins, Robert L. Comis, Allan Topham, Edith P. Mitchell

Publikováno v: Journal of Clinical Oncology. 33:e17598-e17598

e17598 Background: Equitable accrual of underrepresented populations to cancer clinical trials is lacking, resulting in failure to achieve distributive justice in clinical research, and uncertainty...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce114677f986e983e2686bf33c13b1e4
https://doi.org/10.1200/jco.2015.33.15_suppl.e17598

Zobrazit plný text záznamu

Subgroup analysis of African American patients from a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to P plus Cb in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)

Autor: Mark A. Socinski, Donna M. Marinucci, Robert B. Catalano, Chandra P. Belani, Robert L. Comis, Coleman K. Obasaju, J. Treat, René Gonin, Rafat Ansari, Martin J. Edelman

Publikováno v: Journal of Clinical Oncology. 25:18066-18066

18066 Background: A relationship between race and prognosis in patients with NSCLC has been suggested with African Americans (AA) having higher incidence and lower survival rates compared to whites (W) with a similar stage of disease. However, due to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecd08235b21771f8d90687e288f815df
https://doi.org/10.1200/jco.2007.25.18_suppl.18066

Zobrazit plný text záznamu

Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)

Autor: Mark A. Socinski, Robert B. Catalano, René Gonin, Martin J. Edelman, Robert L. Comis, Chandra P. Belani, J. Treat, Donna M. Marinucci, Rafat Ansari, Coleman K. Obasaju

Publikováno v: Journal of Clinical Oncology. 25:7665-7665

7665 Background: Efficacy and safety of platinum-based chemotherapy doublets in elderly (ELD) NSCLC pts with good PS have been reported to be similar to those in younger pts (N-ELD). However, little data exists about which of the standard regimens ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1859e1736d2eff28151cd13d7bde1268
https://doi.org/10.1200/jco.2007.25.18_suppl.7665

Zobrazit plný text záznamu

Minority patients in clinical trials (CT) for advanced non-small cell lung cancer

Autor: Matthew J. Monberg, Robert B. Catalano, Coleman K. Obasaju, Donna M. Marinucci, Robert L. Comis, L. Taylor, J. D. Bloss

Publikováno v: Journal of Clinical Oncology. 23:7153-7153

7153 Background: The ACS projected 2004 incidence of NSCLC in the US is 150,000 new cases. The most recent NCI Surveillance, Epidemiology and End Results (SEER) data report the incidence of NSCLC i...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::650172af1c112ec02fd47b8ca091c7a4
https://doi.org/10.1200/jco.2005.23.16_suppl.7153

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání